The influence of drug-like concepts on decision-making in medicinal chemistry
The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Abstract
The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development. However, despite this acceptance, analysis of recent trends reveals that the physical properties of molecules that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compounds in clinical development. The consequences of the marked increase in lipophilicity--the most important drug-like physical property--include a greater likelihood of lack of selectivity and attrition in drug development. Tackling the threat of compound-related toxicological attrition needs to move to the mainstream of medicinal chemistry decision-making.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“(Note that liophilicity per se may not be relevant, as drugs require carriers to cross membranes [18], and promiscuity and off-target effects increase with lipophilicity [1679].)”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1679]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420 · cited 1×
“Overall oral bioavailability depends not just on absorption but also on dissolution, gut transit time and first-pass metabolism, so it is perhaps surprising that rat bioavailability can be categorized by simple physical properties such as PSA and rotatable bond”
BackgroundLead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,199 · cited 1×
“jpg" NDATA ITEM> ]> Ten years have passed since the publication of the 'rule of five' physical property guidelines for drug permeabilit”
BackgroundCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Budavari, S. (1998) · Royal Society of Chemistry eBooks · Cited by 2,741
ADMET in silico modelling: towards prediction paradise?
van de Waterbeemd, H., & Gifford, E. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1032 · Cited by 1,863
Martin, Y. C. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0492002 · Cited by 1,020 · cited 1×
“, and number of rule-of-five violations, PSA and ionization stat”
BackgroundQuantitative approach to biochemical structure-activity relationships
Hansch, C. (1969) · Accounts of Chemical Research · doi:10.1021/ar50020a002 · Cited by 918 · cited 1×
“This is not surprising: the role of LogP in influencing drug potency, pharmacokinetics and toxicity has been established for many year”
BackgroundMolecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 877 · cited 1×
“This allows the processes of chemical optimization, which frequently increase physical propertie”
Background
Research works printed but not linked: 3
- Kubinyi, H. Lipophilicity and biological activity. Drug transport and drug distribution in model systems and in biological systems. Arzn. Forsch. 29, 1067–1080 (1979).
- Wood, A. Annual Reports in Medicinal Chemistry Volume 41 503–522 (Academic Press, Burlington, 2006).
- Gray, N. Changing Landscapes: A Special Report on the World's Top 50 Pharma Companies. Pharmaceutical Executive web site [online] , (2006)
Cited by
Items 101–200 of 1,006
Cell permeability beyond the rule of 5
Matsson, P., Doak, B. C., Over, B., & Kihlberg, J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.03.013 · Cited by 297
Cooper, T. W. J., Campbell, I. B., & Macdonald, S. J. F. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201002238 · Cited by 299
Selectively Nonselective Kinase Inhibition: Striking the Right Balance
Morphy, R. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901132v · Cited by 292
Targeting protein kinases in central nervous system disorders
Chico, L. K., Van Eldik, L. J., & Watterson, D. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2999 · Cited by 298
Ryckmans, T., Edwards, M. P., Horne, V. A., Correia, A. M., Owen, D. R., Thompson, L. R., Tran, I., Tutt, M. F., & Young, T. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.05.062 · Cited by 270
Fluorine in Medicinal Chemistry
Swallow, S. (2015) · Progress in Medicinal Chemistry · doi:10.1016/bs.pmch.2014.11.001 · Cited by 280
Ward, R. A., Anderton, M. J., Ashton, S., Bethel, P. A., Box, M., Butterworth, S., Colclough, N., Chorley, C. G., Chuaqui, C., Cross, D. A. E., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400822z · Cited by 279
Assessing drug-likeness – what are we missing?
Vistoli, G., Pedretti, A., & Testa, B. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.11.007 · Cited by 278
Ursu, O., Rayan, A., Goldblum, A., & Oprea, T. I. (2011) · WIREs Computational Molecular Science · doi:10.1002/wcms.52 · Cited by 276
Lagorce, D., Douguet, D., Miteva, M. A., & Villoutreix, B. O. (2017) · Scientific Reports · doi:10.1038/srep46277 · Cited by 266
“Magic Chloro”: Profound Effects of the Chlorine Atom in Drug Discovery
Chiodi, D., & Ishihara, Y. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02015 · Cited by 263
Schneider, M., Radoux, C. J., Hercules, A., Ochoa, D., Dunham, I., Zalmas, L.-P., Hessler, G., Ruf, S., Shanmugasundaram, V., Hann, M. M., et al. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00245-x · Cited by 273
Exploring the stability of ligand binding modes to proteins by molecular dynamics simulations
Liu, K., Watanabe, E., & Kokubo, H. (2017) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-016-0005-2 · Cited by 262
Sulfonimidamides in Medicinal and Agricultural Chemistry
Chinthakindi, P. K., Naicker, T., Thota, N., Govender, T., Kruger, H. G., & Arvidsson, P. I. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201610456 · Cited by 271
Pollastri, M. P. (2010) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph0912s49 · Cited by 239
“As a result, oral absorption is becoming a less common source of clinical trial attrition, compared to toxicity (Leeson and Springthorpe, 2007).”
BackgroundLeeson, P. (2012) · Nature · doi:10.1038/481455a · Cited by 266
Self-citationCrawford, J. J., Johnson, A. R., Misner, D. L., Belmont, L. D., Castanedo, G., Choy, R., Coraggio, M., Dong, L., Eigenbrot, C., Erickson, R., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01712 · Cited by 257
Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity
Hill, A. P., & Young, R. J. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.05.016 · Cited by 258
Ligand efficiency as a guide in fragment hit selection and optimization
Schultes, S., de Graaf, C., Haaksma, E. E. J., de Esch, I. J. P., Leurs, R., & Krämer, O. (2010) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2010.11.003 · Cited by 252
Brown, D. G., May-Dracka, T. L., Gagnon, M. M., & Tommasi, R. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501552x · Cited by 253
Early pharmaceutical profiling to predict oral drug absorption: Current status and unmet needs
Bergström, C. A. S., Holm, R., Jørgensen, S. A., Andersson, S. B. E., Artursson, P., Beato, S., Borde, A., Box, K., Brewster, M., Dressman, J., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.10.015 · Cited by 257
Pharmaceuticals that contain polycyclic hydrocarbon scaffolds
Stockdale, T. P., & Williams, C. M. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00477a · Cited by 250
Lai, A., Kahraman, M., Govek, S., Nagasawa, J., Bonnefous, C., Julien, J., Douglas, K., Sensintaffar, J., Lu, N., Lee, K.-J., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00054 · Cited by 247
Meanwell, N. A. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00043 · Cited by 239
Experiences in fragment-based drug discovery
Murray, C. W., Verdonk, M. L., & Rees, D. C. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.02.006 · Cited by 238
Chagas, C. M., Moss, S., & Alisaraie, L. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.07.046 · Cited by 233
Helmy, Y. A., Taha-Abdelaziz, K., Hawwas, H. A. E.-H., Ghosh, S., AlKafaas, S. S., Moawad, M. M. M., Saied, E. M., Kassem, I. I., & Mawad, A. M. M. (2023) · Antibiotics · doi:10.3390/antibiotics12020274 · Cited by 200
“absorption by both host and pathogen barriers [72,73].”
BackgroundAccelerating antibiotic discovery through artificial intelligence
Melo, M. C. R., Maasch, J. R. M. A., & de la Fuente-Nunez, C. (2021) · Communications Biology · doi:10.1038/s42003-021-02586-0 · Cited by 234
“As outliers to original drug-likeness de fi nitions expand the boundaries of these criteria, new qualitative endpoints and quantitative thresholds have come under consideration 80 .”
BackgroundPolypharmacology: The science of multi-targeting molecules
Kabir, A., & Muth, A. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2021.106055 · Cited by 221
Applications of Bioisosteres in the Design of Biologically Active Compounds
Meanwell, N. A. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c00765 · Cited by 211
Stroganov, O. V., Novikov, F. N., Stroylov, V. S., Kulkov, V., & Chilov, G. G. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci800166p · Cited by 223
Natural product drug discovery in the artificial intelligence era
Saldívar-González, F. I., Aldas-Bulos, V. D., Medina-Franco, J. L., & Plisson, F. (2022) · Chemical Science · doi:10.1039/d1sc04471k · Cited by 219
Dearomative ring expansion of thiophenes by bicyclobutane insertion
Wang, H., Shao, H., Das, A., Dutta, S., Chan, H. T., Daniliuc, C., Houk, K. N., & Glorius, F. (2023) · Science · doi:10.1126/science.adh9737 · Cited by 224
Review and analysis of FDA approved drugs using lipid-based formulations
Savla, R., Browne, J., Plassat, V., Wasan, K. M., & Wasan, E. K. (2017) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2017.1342654 · Cited by 225
“This analysis reveals a significantly higher LogP profile than most approved drugs based on an analysis by Leeson and Springthrope looking at LogP and molecular mass trends for pipeline and approved drugs [35].”
MethodAcidic and Basic Drugs in Medicinal Chemistry: A Perspective
Charifson, P. S., & Walters, W. P. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501000a · Cited by 208
Progress in Structure Based Drug Design for G Protein-Coupled Receptors
Congreve, M., Langmead, C. J., Mason, J. S., & Marshall, F. H. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200371q · Cited by 215
Naylor, M. R., Ly, A. M., Handford, M. J., Ramos, D. P., Pye, C. R., Furukawa, A., Klein, V. G., Noland, R. P., Edmondson, Q., Turmon, A. C., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01259 · Cited by 205
Self-Assembled Tat Nanofibers as Effective Drug Carrier and Transporter
Zhang, P., Cheetham, A. G., Lin, Y.-A., & Cui, H. (2013) · ACS Nano · doi:10.1021/nn401667z · Cited by 209
Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update
Roskoski Jr., R. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2021.106037 · Cited by 198
“Leeson and Springthorpe hypothesized that drug lipophilicity, as assessed by its – ALogP value, is one of the more important properties that should be checked during drug development [86].”
BackgroundFrom fragment to clinical candidate—a historical perspective
Chessari, G., & Woodhead, A. J. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.04.007 · Cited by 202
Statins and breast cancer prognosis: evidence and opportunities
Ahern, T. P., Lash, T. L., Damkier, P., Christiansen, P. M., & Cronin-Fenton, D. P. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70119-6 · Cited by 203
Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology
Blagg, J., & Workman, P. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.005 · Cited by 203
“Unsurprisingly, this phenomenon frequently leads to nonspecific effects on multiple proteins and hence misleading observations unrelated to the pharmacology of the component small molecule (Blevitt et al., 2017; Irwin et al., 2015; Leeson and Springthorpe, 2007).”
BackgroundDesigning novel building blocks is an overlooked strategy to improve compound quality
Goldberg, F. W., Kettle, J. G., Kogej, T., Perry, M. W. D., & Tomkinson, N. P. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.023 · Cited by 201
Zhou, H.-J., Wang, J., Yao, B., Wong, S., Djakovic, S., Kumar, B., Rice, J., Valle, E., Soriano, F., Menon, M.-K., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01346 · Cited by 193
Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor
Johnson, D. S., Stiff, C., Lazerwith, S. E., Kesten, S. R., Fay, L. K., Morris, M., Beidler, D., Liimatta, M. B., Smith, S. E., Dudley, D. T., et al. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100190t · Cited by 199
Fish, P. V., Filippakopoulos, P., Bish, G., Brennan, P. E., Bunnage, M. E., Cook, A. S., Federov, O., Gerstenberger, B. S., Jones, H., Knapp, S., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3010515 · Cited by 198
Van Molle, I., Thomann, A., Buckley, D. L., So, E. C., Lang, S., Crews, C. M., & Ciulli, A. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.08.015 · Cited by 188
“These in turn will likely result in poorer physicochemical and pharmacological properties, including lower solubility, poorer cell permeability, and nonspecific toxicity (Leeson and Springthorpe, 2007).”
BackgroundOpportunities for therapeutic antibodies directed at G-protein-coupled receptors
Hutchings, C. J., Koglin, M., Olson, W. C., & Marshall, F. H. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.91 · Cited by 198
Developing inhibitors of glycan processing enzymes as tools for enabling glycobiology
Gloster, T. M., & Vocadlo, D. J. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1029 · Cited by 195
Toxicology Strategies for Drug Discovery: Present and Future
Blomme, E. A. G., & Will, Y. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00407 · Cited by 194
Wawer, M. J., Li, K., Gustafsdottir, S. M., Ljosa, V., Bodycombe, N. E., Marton, M. A., Sokolnicki, K. L., Bray, M.-A., Kemp, M. M., Winchester, E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410933111 · Cited by 196
“Other common strategies include controlling physicochemical parameters (10), exploiting natural selection by sourcing natural products, or relying on natural product-like analogs (11).”
BackgroundChallenges of antibacterial discovery revisited
Gwynn, M. N., Portnoy, A., Rittenhouse, S. F., & Payne, D. J. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05828.x · Cited by 193
An Overview of Machine Learning and Big Data for Drug Toxicity Evaluation
Vo, A. H., Van Vleet, T. R., Gupta, R. R., Liguori, M. J., & Rao, M. S. (2020) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00227 · Cited by 188
Computational prediction of formulation strategies for beyond-rule-of-5 compounds
Bergström, C. A. S., Charman, W. N., & Porter, C. J. H. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.005 · Cited by 187
Murray, C. W., Carr, M. G., Callaghan, O., Chessari, G., Congreve, M., Cowan, S., Coyle, J. E., Downham, R., Figueroa, E., Frederickson, M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100059d · Cited by 184
Ritchie, T. J., Macdonald, S. J. F., Peace, S., Pickett, S. D., & Luscombe, C. N. (2012) · MedChemComm · doi:10.1039/c2md20111a · Cited by 183
Kell, D. B., Dobson, P. D., & Oliver, S. G. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.05.010 · Cited by 186
Ionic liquids for addressing unmet needs in healthcare
Agatemor, C., Ibsen, K. N., Tanner, E. E. L., & Mitragotri, S. (2018) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10083 · Cited by 180
“Compared to the parent drug and its sodium salt, the API-ILs featured high affinity for the cell membrane as revealed by their higher octanol–water partition coefficient,(94) a parameter that describes drugs’ lipophilicity.(95) Indeed, lipophilicity is a determinant of how drugs partition into the lipid bilayer, and h…”
BackgroundInfluentialStructural biology and drug discovery for protein–protein interactions
Jubb, H., Higueruelo, A. P., Winter, A., & Blundell, T. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.03.006 · Cited by 181
Molecular inflation, attrition and the rule of five
Leeson, P. D. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.018 · Cited by 179
Self-citationCyclometallated ruthenium catalyst enables late-stage directed arylation of pharmaceuticals
Simonetti, M., Cannas, D. M., Just-Baringo, X., Vitorica-Yrezabal, I. J., & Larrosa, I. (2018) · Nature Chemistry · doi:10.1038/s41557-018-0062-3 · Cited by 180
Smith, C. R., Aranda, R., Bobinski, T. P., Briere, D. M., Burns, A. C., Christensen, J. G., Clarine, J., Engstrom, L. D., Gunn, R. J., Ivetac, A., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01900 · Cited by 161
Where Do Recent Small Molecule Clinical Development Candidates Come From?
Brown, D. G., & Boström, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00675 · Cited by 176
Drug-like Properties: Guiding Principles for the Design of Natural Product Libraries
Camp, D., Davis, R. A., Campitelli, M., Ebdon, J., & Quinn, R. J. (2012) · Journal of Natural Products · doi:10.1021/np200687v · Cited by 176
Impact of Lipophilic Efficiency on Compound Quality
Tarcsay, Á., Nyíri, K., & Keserű, G. M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201388p · Cited by 164
Shultz, M. D. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.08.029 · Cited by 175
Schönherr, H., & Cernak, T. (2013) · Angewandte Chemie · doi:10.1002/ange.201303207 · Cited by 175
Multi-Parameter Optimization: Identifying High Quality Compounds with a Balance of Properties
D. Segall, M. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799436430 · Cited by 172
New insights from structural biology into the druggability of G protein-coupled receptors
Mason, J. S., Bortolato, A., Congreve, M., & Marshall, F. H. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.02.005 · Cited by 170
Fragment Based Drug Design: From Experimental to Computational Approaches
Kumar, A., Voet, A., & Zhang, K. Y. J. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803530467 · Cited by 168
“To address the challenges of high lipophilicity, which is one of the main causes of increased attrition rate in the clinical trials, Leeson and Springthorpe proposed the ligand lipophilicity efficiency (LLE) index, which subtracts logP from – log10IC50 [39].”
BackgroundKell, D. B., & Goodacre, R. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.014 · Cited by 169
Aungst, B. J. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.12.002 · Cited by 165
Molecular complexity and fragment-based drug discovery: ten years on
Leach, A. R., & Hann, M. M. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.05.008 · Cited by 169
Estrada, A. A., Liu, X., Baker-Glenn, C., Beresford, A., Burdick, D. J., Chambers, M., Chan, B. K., Chen, H., Ding, X., DiPasquale, A. G., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301020q · Cited by 162
An Additive Definition of Molecular Complexity
Böttcher, T. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00723 · Cited by 160
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα
Hanan, E. J., Braun, M.-G., Heald, R. A., MacLeod, C., Chan, C., Clausen, S., Edgar, K. A., Eigenbrot, C., Elliott, R., Endres, N., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01422 · Cited by 158
Advances and Limitations of Antibody Drug Conjugates for Cancer
Mckertish, C., & Kayser, V. (2021) · Biomedicines · doi:10.3390/biomedicines9080872 · Cited by 161
“On the other hand, hydrophilic payloads of the ADC lead to a bystander effect [81].”
BackgroundNext generation of small molecules in inflammatory bowel disease
Olivera, P., Danese, S., & Peyrin-Biroulet, L. (2017) · Gut · doi:10.1136/gutjnl-2016-312912 · Cited by 154
Target-Based Evaluation of “Drug-Like” Properties and Ligand Efficiencies
Leeson, P. D., Bento, A. P., Gaulton, A., Hersey, A., Manners, E. J., Radoux, C. J., & Leach, A. R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00416 · Cited by 176
“78 Lipophilicity 13, 44, 79–81 will remain a key driver of ADMET properties and strategies to assess 82 and control 83,84 it are growing.”
Self-citationChristopher, J. A., Brown, J., Doré, A. S., Errey, J. C., Koglin, M., Marshall, F. H., Myszka, D. G., Rich, R. L., Tate, C. G., Tehan, B., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400140q · Cited by 163
Efficient exploration of chemical space by fragment-based screening
Hall, R. J., Mortenson, P. N., & Murray, C. W. (2014) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2014.09.007 · Cited by 159
Limitations and lessons in the use of X-ray structural information in drug design
Davis, A. M., St-Gallay, S. A., & Kleywegt, G. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.06.006 · Cited by 161
“Rev. 23, 3–25 80 Leeson, P. et al. (2007) The influence of drug-like concepts on decision-making in”
BackgroundLee, K. L., Ambler, C. M., Anderson, D. R., Boscoe, B. P., Bree, A. G., Brodfuehrer, J., Chang, J. S., Choi, C., Chung, S., Curran, K. J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00231 · Cited by 162
The influence of the 'organizational factor' on compound quality in drug discovery
Leeson, P. D., & St-Gallay, S. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3552 · Cited by 162
Self-citationKell, D. B., & Pretorius, E. (2015) · Integrative Biology · doi:10.1039/c5ib00158g · Cited by 160
Visible-Light-Mediated Efficient Metal-Free Catalyst for α-Oxygenation of Tertiary Amines to Amides
Zhang, Y., Riemer, D., Schilling, W., Kollmann, J., & Das, S. (2018) · ACS Catalysis · doi:10.1021/acscatal.8b01897 · Cited by 159
Deeming, A. S., Russell, C. J., & Willis, M. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201409283 · Cited by 158
Methyl-containing pharmaceuticals: Methylation in drug design
Sun, S., & Fu, J. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.09.016 · Cited by 174
Amino Acids as the Nitrogen-Containing Motifs in Copper-Catalyzed Domino Synthesis of N-Heterocycles
Xu, W., & Fu, H. (2011) · The Journal of Organic Chemistry · doi:10.1021/jo2002227 · Cited by 156
Kell, D. B., & Oliver, S. G. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00231 · Cited by 169
“…2014; Sprowl and Sparreboom, 2014) have been highlighting, Smith and colleagues recently published a review (Smith et al., 2014) that claims that the hypothesis that drugs are usually transported into cells via protein carriers is “not a sound scientific principle and lacks experimental evidence.””
BackgroundHigueruelo, A. P., Schreyer, A. M., Bickerton, G. R., Pitt, W. R., Groom, C. R., & Blundell, T. L. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00889.x · Cited by 166
“Lesson and Springthorpe (60) shown in their analysis of small molecule drugs a positive correlation between clogP and promiscuity.”
BackgroundLiang, J., Zbieg, J. R., Blake, R. A., Chang, J. H., Daly, S., DiPasquale, A. G., Friedman, L. S., Gelzleichter, T. R., Gill, M., Giltnane, J. M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00847 · Cited by 155
Fluorine in Drug Design: A Case Study with Fluoroanisoles
Li, X., Blakemore, D. C., Narayanan, A., Unwalla, R. J., Lovering, F., Denny, R. A., Zhou, H., & Bunnage, M. E. (2015) · ChemMedChem · doi:10.1002/cmdc.201402555 · Cited by 155
An in vitro toolbox to accelerate anti-malarial drug discovery and development
Charman, S. A., Andreu, A., Barker, H., Blundell, S. A., Campbell, A., Campbell, M., Chen, G., Chiu, F. C. K., Crighton, E., Katneni, K., et al. (2020) · Malaria Journal · doi:10.1186/s12936-019-3075-5 · Cited by 157
Arikawa, Y., Nishida, H., Kurasawa, O., Hasuoka, A., Hirase, K., Inatomi, N., Hori, Y., Matsukawa, J., Imanishi, A., Kondo, M., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300318t · Cited by 153
Bürli, R. W., Luckhurst, C. A., Aziz, O., Matthews, K. L., Yates, D., Lyons, K. A., Beconi, M., McAllister, G., Breccia, P., Stott, A. J., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4011884 · Cited by 153
Amide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity
Klein, V. G., Bond, A. G., Craigon, C., Lokey, R. S., & Ciulli, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01496 · Cited by 152
Laraia, L., McKenzie, G. J., Spring, D. R., Venkitaraman, A. R., & Huggins, D. J. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.04.019 · Cited by 165
“…as 0.45 kcal/mol per heavy atom and 4.43 (Gleeson et al., 2011; Hopkins et al., 2014), and it has been suggested that drug candidates should have an LE of greater than 0.30 kcal/mol per heavy atom (Hajduk, 2006; Hopkins et al., 2004) and an LLE of greater than 5.00 (Leeson and Springthorpe, 2007).”
InfluentialPeters, J., Schnider, P., Mattei, P., & Kansy, M. (2009) · ChemMedChem · doi:10.1002/cmdc.200800411 · Cited by 150
Physicochemical drug properties associated within vivotoxicological outcomes: a review
Price, D. A., Blagg, J., Jones, L. H., Greene, N., & Wager, T. T. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903042318 · Cited by 167
“The conclusion from this analysis is that the risk of unwanted pharmacologies increases with lipophilicity in each ionization class [27].”
Background
Metadata
- Authors
- Leeson, P. D., & Springthorpe, B.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Leeson, Paul D.
- ORCID
- Leeson, Paul D.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-11
- Volume
- 6
- Issue
- 11
- Pages
- 881-890
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2062458432
- Cited by
- 2,403
- References
- 60
- Citations by year
- 2026: 143 · 2025: 113 · 2024: 140 · 2023: 127 · 2022: 104 · 2021: 144 · 2020: 105 · 2019: 146 · 2018: 119 · 2017: 140 · 2016: 145 · 2015: 140 · 2014: 151 · 2013: 160 · 2012: 165
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Merck
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- drug-likeness, Lipinski's rule of five, lipophilicity, drug attrition, drug discovery, drug selectivity
- MeSH terms
- Chemistry, Pharmaceutical, Decision Making, Pharmaceutical Preparations, Humans, Water, 1-Octanol
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.